What Is Octreotide?

1. How does octreotide work?

Natural somatostatin shuts off many hormones, but enzymes clear it within minutes. Octreotide was built by trimming somatostatin down to its active core and closing it into a ring of eight amino acids held by a disulfide bond. In Bauer and colleagues’ 1982 report, that design made the peptide highly resistant to enzymatic breakdown.

The same paper found it three times more potent than somatostatin at blocking GH release in lab dishes. In rats and rhesus monkeys it was at least 20 times more active, lasted far longer and spared insulin more. Those were animal results. In people, the Sandostatin label describes it as a stronger inhibitor of GH, glucagon and insulin than somatostatin itself.

Somatostatin signals through five receptor types, numbered SSTR1 to SSTR5. When Patel and Srikant tested 32 analogs on all five cloned human receptors, cyclic octapeptides like octreotide bound types 2, 3 and 5 strongly and types 1 and 4 weakly.

According to the labels, octreotide’s effects reach well beyond GH:

2. Injection, monthly depot or capsule: how do the forms differ?

All three brands contain the same peptide; the difference is how fast it gets in and how long it stays. The immediate-release injection acts for up to about 12 hours, so it is usually given three times a day.

The monthly depot

After a single LAR injection, the LAR label describes a small spike in the first hour, a dip over days 3–5, then a climb to a plateau that holds for roughly another 2–3 weeks. Steady state arrives after the third monthly dose. Blood levels swing 44–68% between peak and trough on the depot, compared with 163–209% on three daily injections, and relative bioavailability versus the injection is 60–63%.

In acromegaly at steady state, the label reports trough and peak levels of 1.2 and 1.6 ng/mL on 20 mg, and 2.1 and 2.6 ng/mL on 30 mg.

The oral capsule

Peptides are usually broken down or poorly absorbed when swallowed, the same problem covered in the oral vs injectable GLP-1 guide. Mycapssa’s excipients briefly loosen the junctions between gut-lining cells. In a dedicated study cited on the Mycapssa label, permeability rose 2 hours after a dose and was back to baseline by 5.5 hours.

A 20 mg capsule gave about the same total exposure as a 0.1 mg injection, with a 33% lower peak. Food changes that picture sharply: taken with a meal, peak and total absorption dropped by about 90%. That is why the label requires dosing at least 1 hour before or 2 hours after eating. The bioavailability explainer covers why route and food can change exposure this much.

Who clears it more slowly

The injection label reports a 46% longer half-life in older adults and a half-life of 3.7 hours in liver cirrhosis. Clearance falls to about half of normal in dialysis patients. For the capsule, end-stage kidney disease raised total exposure by 87% and lengthened half-life by 85%.

3. What is octreotide approved for?

Octreotide is a prescription drug in the US. Drugs@FDA lists the capsule approval in 2020; the injection dates from 1988 and the depot from 1998. A multi-dose pen, Bynfezia, and generic injections are also approved.

For the tumor uses, the labels are explicit that octreotide was not shown to reduce tumor size, growth or spread. It treats the symptoms caused by the hormones the tumors release.

Octreotide does not appear on the WADA 2026 Prohibited List. That absence is not evidence of any benefit for athletes.

4. What did the acromegaly trials show?

Injection and monthly depot

A small early trial set the pattern. In Fredstorp and colleagues’ 14-day study of 18 patients, under-the-skin octreotide lowered GH and IGF-1 compared with placebo for the whole treatment period. The average age-adjusted IGF-1 score, measured in standard deviations above normal, fell from 6.47 to 3.60. Insulin dropped 40–48% versus placebo.

The depot was approved on trials that moved patients already controlled on injections to the monthly form. The LAR label averages monthly results across each trial:

Switching to the depot generally held control at least as well. Partial responders did poorly, though: of 25 such patients, only 1 reached GH under 2.5 ng/mL on LAR. In two 48-week open-label studies of 143 previously untreated patients, median tumor volume fell by 20.6% and 24.5% at 24 weeks, and by 36.2% at 48 weeks in the larger study.

Oral capsules

Every capsule trial enrolled people whose disease was already controlled on an injectable somatostatin analog. In the table, ULN means the upper limit of the normal IGF-1 range.

On placebo in OPTIMAL, IGF-1 control was lost after a median of 16 weeks; on capsules the median was not reached. The label adds that about a quarter of capsule patients still needed injectable rescue over 9 months. In the MPOWERED extension, 89.7%, 87.8% and 93.5% of patients who started each year as responders were still responding at the end of years 1, 2 and 3.

How octreotide ranks

Kaparounaki and colleagues’ 2025 network meta-analysis compared 11 treatments across 27 studies and 4,131 patients. Octreotide LAR beat oral capsules for normalizing IGF-1 (odds ratio 5.41). Pegvisomant ranked first overall, followed by pasireotide LAR. The authors cautioned that differences in study design may have shaped these comparisons.

A newer self-injected depot

CAM2029 is a monthly octreotide depot injected under the skin. In the 24-week ACROINNOVA 1 trial, 72 controlled patients were randomized 2:1 to CAM2029 or placebo, and IGF-1 stayed at or below ULN in 72.2% vs 37.5%. The European Commission authorized it as Oczyesa on June 30, 2025.

It is not FDA-approved. According to Camurus’s July 2026 release, the FDA issued a complete response letter on June 10, 2026, linked to a manufacturing inspection, and set a December 18, 2026 target date for the resubmitted application.

5. How is octreotide dosed for acromegaly?

The doses below are the FDA-labeled acromegaly regimens, summarized for reference only. Dose changes are made by the prescriber based on lab results.

Lab targets drive these decisions. The injection label aims for GH under 5 ng/mL or a normal IGF-1, checked every 2 weeks while adjusting. On the depot, GH of 2.5 ng/mL or less with a normal IGF-1 is the threshold for staying at 20 mg. Patients who had pituitary radiation are taken off the drug once a year, for about 4 weeks on the injection or 8 weeks on the depot, to see whether the disease is still active.

6. What are the side effects of octreotide?

None of the three US labels has a boxed warning. Most of the risks follow directly from switching off somatostatin-controlled hormones.

Gallbladder

Because octreotide slows gallbladder emptying and bile flow, stones and sludge build up over time. The Sandostatin and LAR labels report:

Risk tracked with how long someone had been on the drug, not with age, sex or dose. Gallbladder and bile duct inflammation, pancreatitis and one death from ascending cholangitis have been reported, and the labels advise stopping if complications are suspected.

Blood sugar

Lowering insulin, glucagon and GH together means glucose can drift either way.

Heart rate, gut, thyroid and B12

• Heart: in acromegaly patients on the injection, 25% had a heart rate under 50 beats per minute, 10% had conduction abnormalities and 9% had arrhythmias. Complete heart block has been reported with IV use during surgery, mostly at high doses or continuous infusion.
• Digestion: diarrhea, loose stools, nausea and abdominal discomfort each affected 34–61% of acromegaly patients on the injection, and 2.6% stopped because of them. On LAR, diarrhea hit 36.4%, mostly in the first month. In the capsule’s placebo-controlled trial, diarrhea was 29% vs 21%, nausea 21% vs 11% and vomiting 14% vs 0%.
• Fat absorption: reduced pancreatic enzyme and bile acid output can cause fatty stools, bloating and weight loss.
• Thyroid: with TSH suppressed, 12% of acromegaly patients on the injection developed biochemical hypothyroidism, 8% developed goiter and 4% needed thyroid hormone.
• Vitamin B12: low levels have been seen, and the labels recommend checking.
• Injection site: pain was reported by 2%, 9% and 11% of acromegaly patients on LAR 10, 20 and 30 mg.

Pregnancy, children and fertility

Bringing GH and IGF-1 back to normal may restore fertility in women with acromegaly, so the labels warn about unplanned pregnancy; human pregnancy data are limited. Safety and effectiveness in children are not established, and serious events including necrotizing enterocolitis and death have been reported, mostly in children under 2 with serious illness.

7. Octreotide, growth hormone and GH secretagogues

Octreotide acts upstream: it reduces how much GH the pituitary releases, and IGF-1 falls as a result. Two studies show where that effect stops.

• Injected GH still works. Researchers use octreotide to silence the body’s own GH so they can study infused GH. In Hansen and colleagues’ study of 26 healthy men on octreotide, GH infusions still significantly changed IGF-1, free fatty acids and insulin. No study reviewed here tested octreotide alongside long-acting GH products such as somapacitan.
• Secretagogue-driven release can be blunted, at least in tumor cells. Renner and colleagues cultured cells from 12 human GH-secreting adenomas. A GH-releasing peptide raised GH in all of them. Octreotide lowered baseline GH in 5 of 9 cultures tested and, in those, also suppressed the peptide’s effect. This was tumor tissue in a dish, not healthy people.

That second study tested a GH-releasing peptide, not sermorelin, tesamorelin or ipamorelin specifically. No controlled human study has examined octreotide in people using GH, IGF-1 or secretagogues outside medical care, and the evidence gives it no role there. The HGH guide covers what GH itself does and does not do.

8. Interactions, including GLP-1 drugs

The labels list these interactions:

GLP-1 drugs are not named on the octreotide labels, and no study reviewed here paired octreotide with semaglutide or tirzepatide. The overlap that is documented is in the warnings: the Wegovy label lists acute gallbladder disease, including gallstones and gallbladder inflammation, and octreotide’s own labels make gallstones their main long-term concern. Both drugs also act on digestion, and octreotide’s labels flag diabetes medication doses for adjustment.

The contraceptive finding is worth noting for anyone tracking hormones or fertility. It applies to the oral capsule specifically, and the label’s advice is a backup method rather than a dose change.

9. What can you measure or track on octreotide?

Unlike many peptides on this site, octreotide has lab-based treatment targets written into its labels, which list the following checks during acromegaly treatment:

A personal log can help put those results in context. Useful entries include each dose and its timing relative to meals for the capsules, acid reducers or new medications, digestive symptoms in the first weeks, and any upper-right abdominal pain. For the monthly depot, the date of each injection matters because levels take weeks to settle; a half-life model can only approximate that release pattern.

Logs do not replace the lab tests and imaging the labels call for. They make it easier to tell a clinician what changed, and when, if a glucose reading, heart rate or IGF-1 result moves.

10. Octreotide FAQ

• What is octreotide used for?

  Its FDA-labeled uses are acromegaly, where it lowers growth hormone and IGF-1, and the severe diarrhea and flushing caused by metastatic carcinoid tumors and VIP-secreting tumors (VIPomas). The labels state it controls these symptoms but was not shown to shrink or slow the tumors. The oral capsule is approved only for acromegaly maintenance.

• Is octreotide a GLP-1 drug?

  No. Octreotide copies somatostatin, a different hormone that broadly suppresses hormone release. It actually lowers insulin and glucagon secretion, and its labels warn that blood sugar can rise or fall when it is started or the dose changes.

• What are the side effects of octreotide?

  Diarrhea, nausea, abdominal discomfort and loose stools are common, especially early. Over the longer term the labels highlight gallstones and sludge, high or low blood sugar, a slow heart rate, reduced thyroid function and low vitamin B12. None of the three US labels carries a boxed warning.

• How long does octreotide stay in your system?

  After an injection the labeled half-life is 1.7–1.9 hours, with effects lasting up to about 12 hours. The oral capsule's half-life is 2.7 hours in healthy people. The monthly depot is different: in healthy volunteers, levels from a single dose take until weeks 12–13 to fade as the polymer breaks down.

• Does octreotide cause weight loss?

  It is not approved or studied as a weight-loss drug in the sources reviewed here. The labels explain that it can reduce pancreatic enzyme and bile acid secretion, which may cause fatty stools, bloating and weight loss. That is a side effect to report, not a treatment effect.

• Can octreotide be used with semaglutide?

  No study reviewed here tested the combination, and the octreotide labels do not name GLP-1 drugs. Both affect digestion and both list gallbladder problems among their warnings, and octreotide labels call for diabetes drug doses to be adjusted as needed. Any combination is a decision for the prescriber.

• Does octreotide block growth hormone injections?

  No. It reduces how much GH the pituitary releases. Researchers use it to silence natural GH so they can study infused GH, and in that setting the infused GH still changed IGF-1, fatty acids and insulin.

• Is octreotide banned in sport or available without a prescription?

  In the US it is prescription-only. Octreotide is not named on the WADA 2026 Prohibited List. Not being listed says nothing about safety or benefit outside medical treatment.

11. Sources